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Abstract
Background: The content and composition of cerebrospinal fluid (CSF) is determined in large part by the choroid
plexus (CP) and specifically, a specialized epithelial cell (CPe) layer that responds to, synthesizes, and transports
peptide hormones into and out of CSF. Together with ventricular ependymal cells, these CPe relay homeostatic
signals throughout the central nervous system (CNS) and regulate CSF hydrodynamics. One new candidate signal
is augurin, a newly recognized 14 kDa protein that is encoded by esophageal cancer related gene-4 (Ecrg4), a
putative tumor suppressor gene whose presence and function in normal tissues remains unexplored and
enigmatic. The aim of this study was to explore whether Ecrg4 and its product augurin, can be implicated in CNS
development and the response to CNS injury.
Methods: Ecrg4 gene expression in CNS and peripheral tissues was studied by in situ hybridization and
quantitative RT-PCR. Augurin, the protein encoded by Ecrg4, was detected by immunoblotting,
immunohistochemistry and ELISA. The biological consequence of augurin over-expression was studied in a cortical
stab model of rat CNS injury by intra-cerebro-ventricular injection of an adenovirus vector containing the Ecrg4
cDNA. The biological consequences of reduced augurin expression were evaluated by characterizing the CNS
phenotype caused by Ecrg4 gene knockdown in developing zebrafish embryos.
Results: Gene expression and immunohistochemical analyses revealed that, the CP is a major source of Ecrg4 in
the CNS and that Ecrg4 mRNA is predominantly localized to choroid plexus epithelial (CPe), ventricular and central
canal cells of the spinal cord. After a stab injury into the brain however, both augurin staining and Ecrg4 gene
expression decreased precipitously. If the loss of augurin was circumvented by over-expressing Ecrg4 in vivo, BrdU
incorporation by cells in the subependymal zone decreased. Inversely, gene knockdown of Ecrg4 in developing
zebrafish embryos caused increased proliferation of GFAP-positive cells and induced a dose-dependent
hydrocephalus-like phenotype that could be rescued by co-injection of antisense morpholinos with Ecrg4 mRNA.
Conclusion: An unusually elevated expression of the Ecrg4 gene in the CP implies that its product, augurin, plays a
role in CP-CSF-CNS function. The results are all consistent with a model whereby an injury-induced decrease in
augurin dysinhibits target cells at the ependymal-subependymal interface. We speculate that the ability of CP and
ependymal epithelium to alter the progenitor cell response to CNS injury may be mediated, in part by Ecrg4. If so,
the canonic control of its promoter by DNA methylation may implicate epigenetic mechanisms in neuroprogenitor
fate and function in the CNS.
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The choroid plexus (CP) is a unique structure in the
central nervous system (CNS) that is both a major
source of cerebrospinal fluid (CSF) as well as small
molecules, peptides and proteins that maintain overall
brain health, hydrodynamics and homeostasis. The CP
epithelium (CPe) either translocates these factors from
the blood or synthesizes and releases them into the CSF
[1]. As a specialized, yet continuous, extension of the
ependymal epithelium that lines the ventricles in the
brain [2], both CPe and ventricular ependymal cells
share hydrodynamic and homeostatic functions in regu-
lating CSF flow and function [3]. In addition, these
epithelial cells assist in the recovery and regeneration
after CNS injury [4,5]. With an ability to regulate the
fate of neural stem/progenitor cells (NSPCs) that lie in
the physically adjacent subventricular zone (SVZ) of the
ventricular surface [6], both CPe and ependymal epithe-
lial cells are beginning to be viewed as having a central
role in CNS repair [7]. As such, trophic factors pro-
duced by these epithelial cells could have profound
effects on tissue repair and regeneration in the CNS [8].
Modern genomics has generated public databases that
describe the normal distribution of gene expression in
tissues, changes following experimental manipulations of
cell and animal models, and alterations associated with
human disease [9]. Coupled with a multitude of bio-
informatic methodologies publicly available on the Inter-
net and made available by consortia of laboratories,
investigators can now mine these databases to explore
the presence of unique gene sets, the distribution pat-
terns of gene expression, and the possible existence of
unique structural features in predicted gene products.
For example, in 2007 Mirabeau et al [10] extended a
hidden Markov modeling bioinformatics approach ori-
ginally used by Bi et al [11] to search deeper into the
human genome for genes that might encode novel pep-
tide hormones. These investigators then recognized that
a gene that was originally discovered in 1998 [12] and
termed esophageal cancer related gene-4 (Ecrg4) had the
features of a neuropeptide within its primary sequence,
but no known biological function. Instead, it was widely
recognized as being down-regulated in many, if not
most, cancers [12-18]. Markov models of protein pro-
cessing predicted that the Ecrg4 open reading frame
(ORF) encoded at least one, if not several, potentially
highly conserved secreted proteins, one of which Mira-
beau et al [10] termed augurin (Figure 1).
T h ef a c tt h a tt h eEcrg4 gene is down-regulated by
hyper-methylation in many cancers suggests that its epi-
genetic control plays a role in the transformation of nor-
mal cells to cancer [12-18]. Yet little is known regarding
its pathological, let alone, physiological, function in the
C N Se x c e p tt h a ti ti si m p l i c a t e di ns e n e s c e n c e[ 1 9 ] ,
Figure 1 ECRG4 homologies and its predicted processing: A: ECRG4 encodes conserved, potentially secreted proteins. Homologies between
species of Ecrg4 encoded proteins are evident after the primary sequence alignment of the proteins encoded by mouse, rat, human,
chimpanzee, dog, cow, chicken and zebrafish Ecrg4(a) gene were collated from Pubmed (nucleotide) and compared. To aid in functional
comparisons, the sequences were labeled red for small amino acids, blue for acidic and magenta for basic amino acids, green for hydroxyl-,
sulfhydryl, aminated or glycine amino acids. Actual homologies are presented in table 1. Consensus processing sites for (1) removal of the signal
peptide, (2) processing by furin-like hormone substrates and (3) thrombin is highlighted by a line over the sequences. B: Candidate proteins
generated from Ecrg4 gene expression. Eight potential protein products are predicted by algorithms to be generated from the single gene:
intact Ecrg4(1-148); its leader sequence, augurin, argilin and ecilin and their Δ16C-terminal cleaved homologs: CΔ16-augurin, CΔ16-argilin and the
Δ16 peptide itself.
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functions in the brain. It was therefore particularly
interesting to note that publicly available genomic data
bases including Genepaint [11], the St. Jude Brain Gene
Expression Map (BGEM) [20], and the Allen Brain Atlas
[21], showed that Ecrg4 gene expression was signifi-
cantly higher in the CP than other CNS tissues in both
the developing and adult mouse CP (Figure 2). With
this in mind, we explored (1) the relative gene expres-
sion levels of Ecrg4 compared to other tissues,
(2) whether augurin, the 14 kDa peptide product of
Ecrg4, is expressed and secreted by the CP and (3) how
augurin expression is linked to CNS development and
(4) in the CNS injury response.
We show here that there is elevated expression of the
Ecrg4 gene in the CP compared to other CNS and per-
ipheral tissues and that its product, augurin plays a role
in CNS injury. In the adult, Ecrg4 expression in the CP
is decreased following injury, but over-expression
induced by gene transduction is growth inhibitory in the
subependymal zone. In development, gene knockdown
with antisense RNA is growth stimulatory. Taken
t o g e t h e r ,w es u g g e s tan o v e lh o m e o s t a t i cr o l ef o r
augurin in the CNS and propose that a dysinhibition
Figure 2 The choroid plexus and ependyma are major sites of Ecrg4 expression. A: Ecrg4 gene expression in the mouse embryo.
In situ hybridization of mouse embryo day E14.5 were obtained from the GenePaint consortium [51]. Significantly more data is available at:
http://www.genepaint.org/cgi-bin/mgrqcgi94?APPNAME=genepaint&PRGNAME=analysis_viewer&ARGUMENTS=-AQ64622747128404,-AEG,-
A804,-Asetstart,-A5 B: Ecrg4 gene expression in the developing mouse brain. Higher magnification analysis of the CNS localization (from samples
shown in A), shows the in situ hybridization signal localizing primarily to choroid plexus and ependyma. C: Ecrg4 gene expression in the adult
mouse brain. In situ hybridization of adult mouse brain were obtained from open source data generated by the Allen Brain Atlas [21].
Significantly more data throughout the brain are available for analyses at: http://mouse.brain-map.org/brain/1500015O10Rik/70429477/
thumbnails.html?ispopup=1. D: Ecrg4 gene expression in the mouse choroid plexus and ependyma. A higher magnification analysis of the CNS
localization (from samples shown in Panel C), show that the in situ hybridization signal localizes primarily to choroid plexus epithelial cells and to
a lesser extent ventricular ependymal cells. E: Ecrg4 gene expression in mouse central canal ependymal/epithelial cells in the spinal cord. In situ
hybridization maps of adult mouse spinal cord were selected from open source data generated by the Allen Brain Atlas Consortium [21].
Significantly more data on the distribution of Ecrg4 (Riken150001O15) gene expression throughout the mouse spinal cord, including other cell
types, is available at http://mousespinal.brain-map.org/imageseries/show.html?id=100028769. F: Quantitative gene expression by RT-qPCR. After
extracting tissues from donor adult mice (n = 12), highest Ecrg4 expression was found in the dissected choroid plexus. Data was calculated using
the ΔΔCt method and normalized to the values obtained in testes. Similar findings were obtained in a survey of male rats (not shown) and low
gene expression was detectable in all tissues. Error bars represent mean ± standard deviation, n = 5.
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at the ependymal-subependymal interface after CNS
injury. If correct, the canonic epigenetic methylation of
the Ecrg4 gene that characterizes augurin production
[17] may forecast the progenitor response to injury, and
may therefore implicate the CP in defining the regenera-
tive capacity of the CNS.
Materials and methods
Animals, tissues and processing
All animal studies were performed with approval of, and
strict adherence to, either the Institutional Animal Care
and Use Committee of the University of California, San
Diego (La Jolla, CA) or the Home Office (UK) depending
on whether the studies were performed at UCSD or the
University of Birmingham. Human tissues were collected
in accordance to protocols approved by the Brown Univer-
sity Institutional Review Board for human studies and the
Brown University Brain Tissue Resource Center (Provi-
dence, RI). The human samples evaluated here were
obtained during routine autopsy from a 61 year-old male
with no history of neurological disease. Tissue expression
studies were performed using tissue harvested from 20-25
g Balb C mice that were collected after either cervical dislo-
cation or decapitation, immediately frozen on dry ice and
kept at -80°C until analyzed. Male Sprague Dawley rats (n
= 3, 200-250 g) were killed with CO2 inhalation and imme-
diately perfused with 4% formaldehyde in phosphate-buf-
fered saline (PBS), pH 7.4. Breeding zebrafish (Danio rerio)
were maintained at 28°C on 14 h light/10 h dark cycle and
fertilized eggs for morpholinos injections were retrieved
from natural spawning and used immediately.
Antibodies
A polyclonal antibody was raised in chickens by immu-
nization against a recombinant fusion protein that
included the amino acid sequence 71-148 of the full
length predicted product of the Ecrg4 open reading
frame (ORF) by commercial contract to GenWay Bio-
tech, Inc., (San Diego, CA, USA) and antigen affinity
purified to generate purified IgY. Pre-immune IgY was
obtained from the same chicken prior to immunization,
immunoglobulin purified and used as a control. Horse-
radish peroxidase (HRP)-conjugated goat anti-chicken
antibody (BioRad, Hercules, CA, USA) was used as the
secondary antibody in immunoblots. For immunolabel-
ing of augurin in rat tissue, biotinylated donkey anti-
chicken IgG (Stratech, Suffolk, UK) was used for immu-
noperoxidase detection and Alexa Fluor
® 488 or Alexa
Fluor
® 594 (Invitrogen, Paisley, UK) conjugated goat
anti-chicken IgG for immunofluorescence labeling. In
human tissue, the secondary antibody used was biotiny-
lated goat anti-chicken IgG (Vector Laboratories, Burlin-
game, CA, USA).
Adenovirus (Ad)
Ad vector containing either a transgene for Ecrg4
(AdEcrg4) was prepared according to manufacturer’s
instructions using the AdEasy XL Adenoviral Vector
System (Agilent Technologies, Santa Clara, CA, USA).
Primers used to amplify the human Ecrg4 ORF were
5’-TATGTCGACCCGCCATGGCTGCC-3’ (forward)
and 5’-TATAAGCTTAGTAGTCATCGTA-3’ (reverse).
Adenovirus was produced in human embryonic kidney
(HEK) 293 cells and purified and titered with the
Adeno-X Virus Purification Kit (Clontech Laboratories,
Inc., Madison, WI, USA). Ad vector containing a trans-
gene for green fluorescent protein GFP (AdGFP) used as
a control for Ad infection or to visualize infected cells
after intra-cerebro-ventricular (i.c.v.) injection was
obtained commercially (Vector BioLabs, Philadelphia,
PA, USA).
Recombinant protein production
Human Ecrg4 encodes a 148 amino acid protein
(Ensembl: ENSG00000119147), which contains a leader
peptide at residues 1-30 and has predicted processing
sites to generate peptides of 3-17 kDa (Figure 1). One
processed form of the protein encoded by Ecrg4 has
been termed augurin (residues 31-148) [22] but a single
putative pro-hormone cleavage site at residues 68-71
yields two putative peptide hormones at residues 71-148
and 31-70. We have named the fragment 31-70 as ecilin
after the EC part of Ecrg4, and the fragment 71-148 as
argilin after the RG part of Ecrg4. This nomenclature is
used throughout this report. A second predicted proteo-
lytic consensus site for thrombin cleavage generates
C-terminal Δ16 sequences when incubated with throm-
bin (Knowling et al, in preparation). Recombinant
augurin derived from the human cDNA sequence and
corresponding to amino acids 31-148 of the Ecrg4 ORF
was cloned into the pET15b vector following codon and
structural optimization and then over-expressed in
BL21DE3pLysS E. coli (Promega, San Luis Obispo, CA,
USA). The protein was purified to homogeneity by ion-
exchange and gel permeation chromatography.
Penetrating CNS injury model
Adult male Sprague-Dawley rats (n = 3, 200-250 g) were
maintained under standard conditions with access to
food and water ad libitum. Prior to anesthesia, rats
received a subcutaneous injection of buprenorphine
(0.3 mg/kg; Alstoe Animal Health, York, UK) for analgesia.
Rats were then anesthetized with 5% isofluorane (Abbott
Laboratories Ltd, Kent, UK) in oxygen (1.7 L/min). A sim-
ple penetrating CNS injury model used for these studies is
based on a classical injury model [23-25]. Briefly, a sagittal
incision was made over the dorsum of the rat head to
expose the skull, and a knife lesion (3 mm depth) was
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BD Waltham, MA, USA) in the right cerebral cortex
under aseptic conditions. Rats were killed at 1 day post-
lesion and tissues processed for histological analyses as
described below.
I.c.v. injection of AdGFP and AdEcrg4
Following administration of anesthesia as described
above, rats (n = 3 each group) were placed in a stereo-
tactic frame and a sagittal incision was made over the
dorsum of the head to expose the skull surface and
identify bregma. The coordinates used for injection into
the lateral ventricle were: 1 mm posterior to bregma
and 1.5 mm lateral to the midline. With a micro drill,
the skull was punctured and using a Hamilton syringe
placed 4 mm deep into the brain, 20 μl( 2×1 0
9 viral
particles in PBS) of AdEcrg4 for over-expression or AdGFP
for control were injected i.c.v. After injection, the syr-
inge was left in place for 1 min to minimize reflux. Rats
were returned to housing and received a daily intraperi-
toneal (i.p.) injection of 5-bromo-2’-deoxyuridine (BrdU,
10 mg/200 g) on days 2-6 and brains were removed and
processed for analyses as described below.
Database mining and presentation
Gene expression profiles and in situ hybridization data for
Ecrg4 (human C2orf40 [EMBLCDS: AAH21742]) and
mouse Riken1500015O10Rik [EMBLCDS: AAH02254])
distribution in the CNS, were mined from data posted and
publicly available at http://www.genepaint.org [11] and
http://www.allenbrainatlas.org[21]. Partial representative
data presented here is accordance to their citation policies
[11] and readers are referred to the complete data sets
describing Ecrg4 gene expression that are available at their
respective websites for further, in depth analyses.
Immunoblotting, ELISA and RT-quantitative PCR
Immunoblotting
To determine the molecular weight of the Ecrg4 peptide
product expressed in the rodent choroid plexus, total
protein was extracted from adult male rat choroid
plexuses by homogenization and sonication in 1× redu-
cing lithium dodecyl sulfate (LDS) buffer (Invitrogen).
Protein was size-fractionated by polyacrylamide gel elec-
trophoresis (PAGE) on a 4-12% bis-tris gradient gel run
in 2-(N-morpholino) ethanesulfonic acid (MES) buffer
and transferred to a polyvinylidene fluoride membrane.
Chicken anti-augurin antibody or pre-immune IgY
(GenWay) was used to detect augurin. Horseradish per-
oxidase (HRP) conjugated goat anti-chicken antibody
(BioRad) was used as the secondary antibody in Western
blots. An IVIS
® Lumina imaging system (Caliper Life
Sciences, Hopkinton, MA, USA) was used to detect the
chemiluminescent signal.
ELISA
Augurin protein secreted into conditioned media by pri-
mary human choroid plexus epithelial cells was quanti-
fied by competition ELISA (Peninsula Laboratories LLC,
San Carlos, CA, USA) according to manufacturer’s
instructions.
Quantitative RT-PCR (RT-qPCR)
T od e t e r m i n er e l a t i v eg e n ee x p r e s s i o nl e v e l si nd i f f e r e n t
tissues, total RNA from 18 different tissues harvested from
6 month-old male C57BL/6 mice (n = 12) was extracted
using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA)
and reverse transcribed using the iScript cDNA Synthesis
Kit (BioRad). All RT-qPCR runs were performed in dupli-
cate, and the amplification cycle threshold (Ct) for Ecrg4
was normalized to glyceraldehyde-3-phosphate (GAPDH)
using SYBR green detection (BioRad). Ecrg4 expression
levels were normalized to levels in testes. Amplification
cycle parameters were as follows: 95°C denaturation, 60°C
annealing and 72°C elongation. Efficiencies for both pri-
mer sets as determined by standard curve analysis were
95-100%. Primer sequences for Ecrg4 were as follows:
Ecrg4 forward 5’-AAGCGTGCCAAACGACAGCTGTGG
GAC-3’; Ecrg4 reverse 5’-TTAATAGTCATCATAGTT-
GACACTGGC-3’;G A P D Hf o r w a r d5 ’-GCACAGT-
CAAGGCCGAGAAT-3’; GAPDH reverse 5’-GCCTT
CTCCATGGTGGTGAA-3’.
Immunostaining
Human paraffin-embedded brain tissue
Human CP tissue was obtained at autopsy, fixed in neu-
tral-buffered formalin (NBF), and paraffin embedded.
After preparing 8 μm sections, tissue was deparaffinized
and rehydrated. For antigen retrieval, the tissue was
incubated in 10 mM citrate, pH 6 at 85°C for 20 min
and rinsed. Sections were quenched with peroxidase
blocking reagent (Dako, Carpinteria, CA, USA) and
blocked with 5% normal goat serum and incubated in
0.5 μg/ml chicken anti-augurin IgY (GenWay). Biotiny-
l a t e dg o a ta n t i - c h i c k e ns econdary antibody (Vector
Laboratories) was used at 2 μg/ml. Augurin immunor-
eactivity was detected using the standard avidin-biotin
immunoperoxidase complex method as described else-
where [26] with reagents from Vector Laboratories.
Rat brain tissue analyses
Sham and injured rats were euthanized in a CO2 cham-
ber, trans-cardially perfused with PBS and then fixed
with 4% paraformaldehyde (PFA) in PBS pH 7.4. Brains
were dissected and post-fixed overnight at 4°C in PBS
containing 20% sucrose and 4% PFA. Tissues were then
rinsed overnight at 4°C in PBS containing 30% sucrose
and rapidly frozen into OCT compound (Miles Labora-
tories, Naperville, Il. USA) on dry ice and stored at -80°C.
For the analyses of the injury response, 15 μm thick coro-
nal brain sections were placed on charged microscope
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AdEcrg4 transgene over-expression, frozen coronal brain
sections (28 μmt h i c k )w e r ec o l l e c t e da n ds t o r e df r e e -
floating in cryoprotectant solution (50% 0.05 M sodium
phosphate buffer, 30% ethylene glycol, Sigma, Dorset,
UK., 20% glycerol, Sigma). To block non-specific binding,
tissue sections (15 μm) were first incubated for 20 min at
25°C in PBS containing 0.3% Tween 20, 2% Bovine
Serum Albumin (BSA, Jackson ImmunoResearch, Suffolk,
UK) and 15% normal goat serum (Vector, Peterborough,
UK). Sections were drained and incubated at 4°C over-
night in chicken anti-augurin IgY (2 μg/ml). Sections
were then rinsed in PBS containing 0.3% Tween and then
incubated in 1 μg/ml 488 Alexa Fluor
® goat anti-chicken
(Invitrogen) for 45 min at 25°C. Finally sections were
rinsed and mounted with mounting media containing
4’,6-diamidino-2-phenylindole for nuclear counterstain
(DAPI, Vector Labs). Staining was visualized under an
epifluorescent (Zeiss) or confocal microscope (Zeiss
LSM510). Pre-immune IgY was used as negative control
for augurin staining. In some instances localization of
augurin was performed by immunoperoxidase staining,
using the standard avidin-biotin peroxidase complex
method (Vector) and reaction visualized with diamino-
benzidine (DAB, Vector) as substrate.
Free-floating sections were also used for immunostaining
of augurin, GFP, nestin and BrdU after i.c.v. injections of
AdGFP and AdEcrg4.a n da f t e ri . p .i n j e c t i o n so fB r d U .F o r
BrdU staining, sections were initially treated with 1 M HCl
at 45°C for 30 min prior to immunostaining. To block
non-specific binding, sections were incubated with 2% BSA
and 15% normal goat serum in PBS pH 7.4 for 1 h. Sec-
tions were then incubated with either chicken anti-augurin
IgY (0.5 mg/ml) for 1 h at room temperature (RT) or
with sheep anti-BrdU IgG (10 mg/ml, Sigma) overnight at
4°C. Finally the sections were rinsed and incubated with
1 mg/ml of either Alexa Fluor
® 594 goat anti chicken or
donkey anti-sheep (Invitrogen) for 45 min at 25°C. Sections
were then mounted on slides, covered with mounting
media containing DAPI and the staining visualized under
an epifluorescent (Zeiss) or confocal microscope (Zeiss
LSM510). Mouse anti nestin was obtained from BD Bios-
ciences (556309), blocked in 10% normal goat serum in
PBS/Tween/2%BSA and incubated at 1/200 in PBS/
Tween/BSA overnight at 4°C. Alexa 594-labeled anti
mouse 1/1000 was incubated for 45 min at RT for fluores-
cence labeling (Invitrogen). Pre-immune IgY was used as
negative control for augurin staining. Multiple Z-stacks
were taken from each animal of the BrdU staining
observed in the SVZ and BrdU-positive cells were counted
manually while blinded to the treatment group of the ani-
mals. GFP was detected by direct fluorescence. To deter-
mine the significance of differences in BrdU-positive cells
in AdGFP -a n dA d Ecrg4 - injected animals, statistical analysis
was performed using Student’s T-test with equal variances
after confirming independence of the variables.
In situ Hybridization
Restriction enzyme linearized (Sal I) plasmid pCMV-Sport
6 expressing the mouse Ecrg4 cDNA was purchased from
Origene (#MC200116) and used as template for the gen-
eration of digoxigenin-labeled RNA probe using T7 poly-
merase as indicated by manufacturer’sr e c o m m e n d a t i o n s
(# 11-175-025-910, Roche, Indianapolis, IN, USA). Control
RNA probes were generated from pSPT18-Neo plasmid
while labeling efficiency was verified by dot blot compari-
son of RNA probes with pre-labeled standards provided in
the kit. Rat tissues were processed as described for immu-
nohistochemical analyses. Brain tissue sections (15 μm)
were washed in PBS, permeabilized with PBS containing
0.1% Triton X-100 (Sigma) and acetylated for 15 min in
0.1 M triethanolamine (Sigma) pH 8.0 containing 0.25%
(v/v) acetic anhydride (Sigma). Sections were then rinsed
in 0.2 × SSC (Sigma) and incubated for 15 min at 52°C in
pre-hybridization buffer (4 × SSC containing 50%
de-ionized formamide, Sigma). Sections were hybridized
for 16 h at 52°C with DIG-labeled complementary RNA or
control RNA probe diluted in hybridization buffer con-
taining 40% de-ionized formamide, 10% dextran sulfate
(QBiogene, Cambridge, UK) 1× Denhardt’ss o l u t i o n
(Sigma), 4 × SSC, 10 mM DTT (Roche Diagnostics,
Mannheim, Germany), 1 mg/ml yeast t-RNA (Invitrogen)
and 1 mg/ml denatured and sheared salmon sperm DNA
(Roche Diagnostics). Non-specific binding was removed
by washes in 2 × SSC at 37°C and single stranded RNA
probe digested by incubating the sections for 30 min at
37°C in NTE (500 mM NaCl, 1 mM EDTA, 10 mM Tris
pH 8.0) buffer containing 20 μg/ml RNase A (Worthing-
ton Biochemical, Reading, UK). Sections were then rinsed
i n0 . 1×S S Ca t4 5 ° Cf o r1h ,r i n s e di n1 0 0m MT r i sp H
7.5 containing 150 mM NaCl. Sections were then blocked
with 100 mM Tris buffer containing 0.1% Triton X100
and 10% normal sheep serum (Jackson ImmunoResearch)
for 30 min, drained and incubated for 2 h at 25°C in anti-
digoxigenin-POD, Fab fragment (1/50 Roche Diagnostics)
diluted in 100 mM Tris, 0.1% Triton X100 and 2% normal
sheep serum. Sections were rinsed, incubated in DAB sub-
strate (Vector) for 10 min, rinsed in distilled water, dehy-
drated and mounted. Slides were analyzed and pictures
taken under a bright field microscopy (Axioplan, Zeiss).
Cell culture and transduction of human choroid plexus
epithelial cells
Primary human CPe cells were obtained from ScienCell
Research Laboratories (Carlsbad, CA, USA) and cultured
according to distributor’s recommendations. HEK 293
(ATCC, Manassas, VA, USA) cells were cultured under
standard conditions as described previously [27]. CPe
and HEK cells were transduced with AdEcrg4 or AdGFP at
a multiplicity of infection (MOI) of 100. Expression of
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noblotting as described above.
Zebrafish morpholino treatments and analyses
A 25 base pair anti-sense morpholino, synthesized by
GeneTool, was designed to target the 5’ untranslated
region to block protein translation of zebrafish Ecrg4a
(zgc:112443 [EMBLCDS:AAH93311]). A standard control
morpholino was also purchased to assess non-specific
effects caused by injection and morpholino dosing. Speci-
fically, the sequence of the standard negative control
morpholino used in the experiments described here was:
5’-CCTCTTACCTCAGTTACAATTTATA-3’ which tar-
gets a human b-globin intron mutation and has not been
reported to have other targets or generate any pheno-
types in any known Zebrafish test systems. The Ecrg4a
morpholino (5’-TTCTGCTCTTCTCCTTCTTCTCTGT-
3’) targets the 5’ untranslated region and recommended
by morpholino selection algorithms accessed through
http://www.zfin.org.
The Ecrg4a open reading frame was cloned using PCR
from the zgc:112443 cDNA clone (Open Biosystem) and
the fragment ligated into a pCS2+ expression vector.
Capped mRNAs were synthesized with linearized
Ecrg4a-pCS2+ by mMessage SP6 kit and purified with a
Qiagen RNeasy mini Kit. Microinjections into 1-2 cell
embryos used 1 nl of 0.5 mM control morpholinos, or
1n lo f0 . 0 6t o0 . 1 2 5m Ma n t i - Ecrg4a morpholino for
low or high dosages respectively in a Warner Instrument
Picoliter Pressure Line injector (PLI-100). In mRNA res-
cue experiments, 1nl solution containing 25 pg of
capped Ecrg4a mRNA was injected with 0.125 mM
Ecrg4a morpholino. Photographs were taken at different
stages and phenotypic changes documented. To visualize
the CNS effects of anti-Ecrg4a morpholino injections,
the area of CNS edema was identified by lasso and
cropped from images, printed and cut from photographs
that had been equally enlarged using Preview (Apple,
Cupertino, CA, USA). These areas were measured and
reported as artificial optical units. Quantification of the
effect of Ecrg4 and control morpholinos on the size of
the zebrafish ventricles was also performed by image
analysis using NIH imageJ of stage-matched 48 h
embryos. Data was exported to MS-Excel for analyses.
Whole-mount immunocytochemistry of zebrafish embryos
embryos (48 h) were fixed in 4% PFA in PBS overnight at
4°C and permeabilized with -20°C acetone. After blocking
with 15% normal donkey serum, rabbit polyclonal anti-
H3P and mouse monoclonal zrf-1 (anti-GFAP) antibo-
dies were incubated with embryos at 4°C overnight. After
washing, Alexa Fluor
® 488-labeled anti-mouse and Alexa
Fluor
® 555-labeled anti-rabbit secondary antibodies were
used for detection and the embryos were subsequently
mounted in custom made chambers for imaging by laser
scanning confocal or epi-fluorescence microscopy.
Quantification of cell proliferation in zebrafish embryonic
brain
In order to measure the effects of the anti-ECRG4 mor-
pholino on cell proliferation, the z-projections of confo-
cal stacks obtained from H3P/GFAP double staining
images were converted to binary images by adjusting the
threshold differentiating H3P positive cells from back-
ground. The amount of signal by was determined by
measuring the percentage of area occupied by the H3P
positive cells in brain regions defined by GFAP staining
in projected images. The ‘analyze particle’ function in
NIH ImageJ was used to perform the measurement and
data was exported to MS-Excel for analyses.
Results
Expression of Ecrg4 in the mammalian choroid plexus
An alignment of the proteins encoded by the Ecrg4 open
reading frame demonstrates the extent of sequence
homology between species (Table 1 and Figure 1).
Accordingly, we generated a chicken polyclonal antibody
specific to the more conserved C-terminus of augurin
for use in immunohistochemistry and ELISA assays, rea-
soning that the antibodies generated would cross-react
among different species. Whereas the Ecrg4 open read-
ing frame encodes a 148 amino acid protein however,
post translational processing can potentially produce 8
peptides (Figure 1B) that include the (1) the full length
Ecrg4 protein, (2) cleavage of the leader peptide from
ECRG4 to generate the fragment called augurin [10],
and two others that we termed ecilin (EC) and argilin
(RG) that are predicted to be generated by furin-like
cleavage and another two forms of augurin and argilin
that are predicted from a thrombin consensus cleavage
site that would release the last 16 amino acids of the
carboxyl terminus peptide (Figure 1) to generate CΔ16-
augurin and CΔ16-argilin. For purposes of clarity, this
nomenclature is used throughout this manuscript.
Table 1 The ECRG4 open reading frame shows high
evolutionary conservation
Species Gene Protein Homology to
human
Homo sapiens C2orf40 NP_115787.1
Mus musculus 1500015O10Rik NP_077245.1 84%
Rattus norvegicus RGD1305645 XP_343563.1 83%
Pan troglodytes LOC459473 XP_001164223.1 99%
Bos taurus ECRG4 NP_001033202.1 81%
Canis lupus
familiaris
LOC611190 XP_853925.1 89%
Gallus gallus LOC771055 XP_001234361.1 58%
Danio rerio (A) zgc:112443 NP_001017697 47%
Danio rerio (B) BC095747.1 P0CAX4.1 42%
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[11] and the Allen Brain Atlas [21] revealed that the
expression of Ecrg4 in the developing CNS of the mouse
embryo at stage E14.5 localizes primarily to the choroid
plexus (Figure 2A). While there are also other loci of
abundant probe hybridization indicating Ecrg4 gene
expression, for example in heart and cartilage [10,28], the
localization pattern in mouse CNS may suggest a role in
CP and ependymal function. In the developing mouse
embryo, the localization of Ecrg4 mRNA in CPe is clearly
evident (Figure 2B) and is also present in adult brain
(Figure 2C). A less intense signal was also detected
throughout the brain parenchyma in what appear to be
neurons by immunohistochemistry of human and rat
brains (Miller et al, and Gonzalez et al, in preparation).
In the adult mouse brain, Ecrg4 mRNA localized to CPe
(Figure 2D) and the epithelial lining of the central canal
(Figure 2E, inset). Probe hybridization was also observed
in the gray matter of the spinal cord (Figure 2E). A survey
of various tissues by real-time PCR underscored the fact
that the CP is a major site of Ecrg4 gene expression in the
adult mouse (Figure 2F) and similar results were found in
rat (data not shown). Although gene expression is detect-
able in other tissues (i.e. adrenal, pancreas, heart and skin),
expression was relatively low compared to the signal from
CP tissues.
Localization of the Ecrg4 product augurin to the CPe
Augurin-immunoreactive protein localized to CP and
ventricular ependymal cells of adult rat brain (Figure 3A)
as predicted by the gene expression data shown in Fig-
ures 2C, D and 2F. There was no specific staining
observed in tissue incubated with the pre-immune IgY
(Figure 3A, inset) and a similar pattern was detected in
Figure 3 The choroid plexus expresses augurin, a 14 kDa processed protein form of the ECRG4 ORF corresponding to amino acids
31-148. A: Immunostaining in rat brain: Immunoreactive augurin was present in the choroid plexus (arrow) and ependyma (arrowhead) of the
third ventricle in the adult rat compared to pre-immune IgY control (top inset). Scale bar = 20 μm B: Immunostaining in human brain: Adult
human tissue showed that similarly, augurin staining localized primarily to the epithelial cell layer of the human CP (black arrow). Scale bar = 20
μmC: Immunoblotting of rat choroid plexus. When rat CP tissue was extracted and analyzed by immunoblotting as described in the text, an
immunoreactive 14 kDa band was detected. It corresponds to the anticipated molecular weight of augurin. D: Augurin secretion in vitro: When
adult primary human CPe cells were transduced with an adenovirus vector containing the green fluorescent protein gene (AdGFP), they were
fluorescent (not shown) and like untreated CP cells in culture, do not express augurin. When these cells are transduced with adenovirus vector
containing Ecrg4 cDNA (AdEcrg4), augurin protein can be detected in RIPA lysates by immunoblotting and the AdECRG4-transduced CPe cells
secrete augurin into the conditioned medium that can be measured by ELISA but not detected by immunoblotting. M = molecular weight
markers and rAugurin = recombinant augurin used as standard and purified from, E coli.
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(Figure 3B), cytoplasmic and in some cells, apical staining
was observed (Figure 3B, arrow) that appeared in many
instances to be localized to the plasma membrane sug-
gesting polarized cell surface localization. Immunoblot-
ting with the anti-augurin antibody after PAGE size
fractionation of rat CP extracts, showed that the endo-
genous form of CP-derived immunoreactive protein is
14 kDa (Figure 3C), the predicted molecular weight of
augurin Ecrg4(31-148). This size is consistent with pro-
cessing to remove the leader sequence Ecrg4(1-30) as
predicted by Mirabeau et al [20]. Unlike neurohypophy-
seal extracts (A. Roberton, personal communication and
[20]), immunoblotting did not reveal significant presence
of the further processed peptides (Figure 1) [10] includ-
ing ecilin, the peptide corresponding to Ecrg4 amino
acids 31-70, or argilin, the peptide corresponding to the
C-terminus Ecrg4 amino acids 71-148 (Figure 1). Longer
detection times of the immunoblotting membranes show
trace amounts of an 8 kDa peptide, that could corre-
spond to argilin and a 28 kDa peptide could be an
augurin dimer that is not dissociated by sample boiling
or detergent disruption (S.E. Knowling, unpublished
observation).
Augurin was secreted into culture media conditioned by
transduced human CPe cells
The processed product of the Ecrg4 gene is presumed to be
a secreted protein [19,28] because the ORF contains a con-
sensus leader sequence that directs augurin into the endo-
plasmic reticulum and Golgi apparatus for translocation
outside of the cell. To determine whether CP-derived
augurin could be secreted in to media by CPe cells, we
used a quantitative ELISA assay to analyze the conditioned
media of AdEcrg4-transduced cultured primary human CPe
cells versus control cells (AdGFP-transduced CPe cells). Pre-
sumably because Ecrg4 is down regulated in injury pheno-
types like cell culture (unpublished observations), we were
not able to detect endogenous Ecrg4 protein expression in
this or several other cell lines assayed (Figure 3D and
unpublished results). It is possible that Ecrg4 expression is
lost as cells are selected for their ability to grow in culture
because Ecrg4 expression has been linked to senescence
and cell cycle arrest [12-18]. Following AdEcrg4 gene trans-
duction and consequent transgene over-expression how-
ever, the CPe cells do express, process and secrete augurin
(Figure 3D). CPe cells transduced with AdEcrg4 expressed
an immunoreactive augurin that could be detected by
immunoblotting of cell lysates and ELISA of conditioned
media (Figures 3D, E). As expected, no signal was observed
in AdGFP-transduced CPe cells or conditioned media.
Together these results suggest that there is cell-type pro-
cessing to produce a 14 kDa augurin and when expressed
by CPe cells, it can be secreted into media.
Immunoreactive augurin in the rat choroid plexus
decreased following CNS injury
Although Ecrg4 gene expression is well described as
down-regulated in cancer and inversely correlated with
cell proliferation [13-16], there is little known regarding
its fate and distribution in the CNS [19]. To examine
whether augurin might participate in the CP response to
CNS injury, we first asked if there is a change in augurin
immunoreactivity in CP after a penetrating injury to the
cerebral cortex in the adult rat. Previous studies have
established that significant changes in CP function
accompany CNS injury, stroke and trauma [4,8,29,30]. As
s h o w ni nF i g u r e4 ,a u g u r i np r o t e i ni nr a tC P ec e l l sw a s
decreased 24 h after penetrating CNS injury (Figure 4B
relative to 4A). Furthermore, because in situ hybridiza-
tion shows that gene expression is decreased 24 h after
injury (Figure 4D relative to 4C), the loss of augurin
staining is presumed to represent increased secretion and
inhibited gene expression.
Functional consequences of Ecrg4 expression after the
cortical stab model of CNS injury
To ask whether there might be a correlation between
augurin expression in the CPe and recovery from injury,
we examined the effect of Ecrg4 transgene delivery, and
t h u sa u g u r i no v e r - e x p r e s s i o n ,o nB r d Uu p t a k ei nS V Z
cells following an i.c.v. injection of AdEcrg4 versus AdGFP.
We hypothesized that because Ecrg4 is down-regulated in
proliferating cells like tumors and cells in culture
[13-17,28] but upregulated in senescent cells [19], then
augurin over-expression might affect the proliferation
response to injury in the SVZ. Accordingly, we injected
either AdEcrg4 or AdGFP into rat brains i.c.v. to transduce
ependymal and CPe cells [31]. We then injected
5-bromo-2’-deoxyuridine (BrdU) i.p. to label mitotic cells
proliferating in the SVZ following CNS injury [6]. First,
we confirmed the ependymal localization of transduction
after i.c.v. injections of Ad by examining GFP staining
(Figure 5A). These findings confirmed the adenoviral
tropism for ventricular ependyma that has been used by
others for gene delivery to CPe and peptide delivery to
CSF [32]. In uninjured adult animals, very little BrdU
incorporation has been observed in the SVZ of the brain
[33]. After cortical stab injury in AdGFP-treated rats,
there were BrdU-labeled cells that were detectable by
immunohistochemical staining for BrdU (Figure 5B, red).
However, the number of BrdU positive cells was signifi-
cantly decreased with AdEcrg4 injections (Figures 5C and
5D). Taken together, these data suggest that augurin pro-
duced by ependyma and CPe, could have a role in regu-
lating the proliferation rate of subependymal cells
presumably, NSPCs. If so, it was important to test the
possibility that the loss of augurin immunoreactivity that
is observed after injury (see Figures 4A and 4B) might
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them to proliferate.
Ecrg4 targets nestin-positive neuroepithelial progenitor
cells
The possibility that Ecrg4 over-expression inhibits NSPC
activation in the SVZ after injury, is consistent with the
predicted inhibitory effects of Ecrg4 gene expression on
other cell types, particularly tumor cells [12-18]. For this
reason, it was important to determine if BrdU-labeled
cells increased by injury and blocked by Ecrg4 over-
expression, were indeed NSPCs. We therefore examined
the distribution of nestin immunoreactivity in the SVZ.
Nestin is expressed in dividing cells during the early
stages of development and its expression levels decrease
with differentiation, but levels are elevated after CNS
Figure 4 Augurin immunoreactivity and Ecrg4 gene expression decreases in the CP following CNS injury.Aa n dB :A u g u r i n
immunoreactivity decreased in rat choroid plexus after penetrating CNS injury. A: Augurin immunoreactivity in the brains of control rats was, as
anticipated, readily detectable in the cytoplasm of CPe cells. In certain areas, this staining appeared apical. B: There was an apparent decrease in
augurin at 1 day post injury (d.p.i.). Augurin: red, DAPI: blue, scale bar = 20 μm. C and D: Ecrg4 gene expression decreased in rat choroid plexus
after penetrating CNS injury. C: Ecrg4 gene expression in the brains of control rats was, as anticipated, readily detectable by in situ hybridization
in the cytoplasm of CP epithelial cells. D: As shown in Panel D however, there was an apparent decrease in Ecrg4 gene expression staining in
the CP-containing sections processed from animals 24 h post injury (d.p.i.). Scale bar = 20 μm.
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the SVZ (Panel 6A, red) and in ventricular subependy-
mal cells (Panel 6C) of AdGFP-treated rat brains. The
AdEcrg4 -treated rat brains however were virtually devoid
of nestin staining in both SVZ (Panel 6B) ependyma and
subependyma (Panel 6D). Furthermore, nestin staining
in other unrelated CNS areas (e.g. subfornical organ),
was unchanged by AdEcrg4 (not shown) indicating that
t h ei n j u r yr e s p o n s ea f f e c t e db yEcrg4 over-expression is
local.
Knockdown Ecrg4 gene expression during development
inhibits cell growth and induced hydrocephalus-like edema
Because Ecrg4 over-expression during injury results in
inhibition of NSPC proliferation (Figures 4 and 5), we pre-
dicted that Ecrg4 gene knockdown might result in
Figure 5 Ecrg4 over-expression inhibits injury-induced proliferation of subependymal progenitor cells. A: Transduction of ependyma
with adenovirus vector containing the green fluorescent protein gene (AdGFP). If AdGFP was injected i.c.v. such that target cells were labeled
prior to the penetrating injury, ependymal cells throughout the ventricles were transduced as indicated by the GFP staining of ependyma
(green). Scale bar = 100 μm. B: Cell proliferation after penetrating injury after AdGFP. To monitor cell growth after injury, animals that had been
injected with AdGFP, received daily injections of BrdU i.p. as described in the text and the incorporation of BrdU into DNA was evaluated by
immunohistochemistry. Brdu: red, DAPI: blue, scale bar = 20 μm. C: Cell proliferation after penetrating injury and AdEcrg4. If instead of AdGFP as
above, the target ependymal cells were transduced by i.c.v. injection of adenovirus containing Ecrg4 (AdEcrg4), there was a decrease in BrdU-
labeled cells in the subependymal zone. Scale bar = 20 μm. D: Quantification of cell proliferation after penetrating injury after AdGFP or AdEcrg4.
When apparent differences in proliferating cell number were quantified, a significant difference in proliferating cell number was observed (p <
0.01). Error bars represent mean ± standard deviation (n = 4).
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opmental knockdown model of Ecrg4 gene expression
in vivo to further analyze augurin function in the CNS.
The developing zebrafish was selected while awaiting the
generation of a knockout mouse model [22,35,36].
In developing zebrafish, the functional knockdown of
specific genes has been proven effective [37] and it is widely
accepted as a surrogate technique to mammalian gene ana-
lysis [38,39]. The model exploits transparent embryos and,
because the ventricles are highly visible, and the CP well-
Figure 6 Nestin immunoreactivity is decreased in the subependymal zone following Ecrg4 over-expression.Aa n dC :N e s t i n
immunoreactivity in rat subependymal zone. When examined under low (Panel A, 200×) or higher (Panel C, 400×) magnification, nestin
immunoreactivity labeled neuroepithelial progenitor cells that were present and proliferating after the i.c.v. injection of AdGFP into injured rat
brains. Nestin was also detectable in the ependymal cell layer as denoted by arrows in the ventricle (v) where it co-localized with GFP positive
cells. Blue = DAPI, Red = nestin, green and yellow = GFP in AdGFP positive cells. B and D: Nestin immunoreactivity decreased in subependyma
after ADEcrg4 injection. There was decreased nestin staining that was readily observed in the subventricular zone of AdEcrg4 treated rat brains
when examined under low (Panel B, 200×) or higher (Panel D, 400×) magnification. These are the same zones where BrdU incorporation was
also decreased (see Figure 5). The ependymal cell layer is denoted by arrows in ventricle (v). Blue = DAPI, Red = nestin Scale bar = 20 μm.
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Ecrg4 function in the CNS. To this end, Ecrg4a morpholinos
(MOs) were injected into developing zebrafish embryos at
1-2 cell stages using either a control MO (Figure 7A1) or
an antisense Ecrg4aM O s( F i g u r e7 A 2 ) .T h ed e v e l o p m e n to f
embryos was then observed for 120 h. Within the first 48 h,
severe defects in CNS development were observed in the
Ecrg4a MO group including a brain ventricular hydroce-
phalus-like edema phenotype. A second Ecrg4aM Ow a s
used to confirm and validate the reproducibility of the
Ecrg4 knockdown phenotype (not shown). Specificity of the
effects of Ecrg4a knockdown was confirmed by near-
complete rescue by quenching the morpholinos with a
co-injection of the Ecrg4aM Ow i t hEcrg4am R N A
(Figure 7B). To determine the effect of Ecrg4a knockdown
on CNS cell proliferation, control and Ecrg4aM O - i n j e c t e d
embryos were processed for whole mount immunostaining
and analyzed using an antibody against phosphorylated his-
tone-3 antibody (H3P) that is a marker for proliferating
cells in developing Zebrafish [41]. In these experiments
(Figures 7C, D and 7E), we observed that Ecrg4a MO treat-
ment increased cell proliferation in the developing CNS.
Figure 7 ECRG4 gene knockdown causes enlarged hindbrain ventricles and a hyper proliferative response in the developing zebrafish.
A: Development of Zebrafish after morpholino injection 48 hours post fertilization. In control (A1) and Ecrg4 (A2) morpholino treatments, the
head, eyes, heart, yolk and hind ventricle (arrows) were photographed for analysis. The anti-sense Ecrg4a morpholino caused readily detectable
hindbrain ventriculomegaly resembling a hydrocephalus-edema-like response in the CNS. The ventricles can be isolated from images for analyses
(n = 8). B: Quantification of developmental effects of morpholino injection. Hindbrain ventricle size was quantified by pixel area of microscope
images from n = 8 control (MO ctl), n = 8 Ecrg4a MO-treated embryos or (n = 8) Ecrg4a MO co-injected with the Zebrafish mRNA ortholog A to
neutralize specific inhibition (error bars: mean ± standard deviation). C-E: Cell growth in Zebrafish 24 hours after control or Ecrg4a morpholino
injection 24 hours post fertilization. Proliferating cells in control MO (top panels) from sagittal (C1), dorsal (D1) or after cross sections at dashed
line (E1) can be compared to similar sections of Ecrg4a MO (bottom panel) injected animals by staining for phosphorylated Histone 3 (H3P,
green), a marker of cell growth. H3P-positive proliferating cells are compared to that of cytoplasmic glial fibrillary acidic protein (red). The arrow
(D2) highlights space corresponding to enlarged ventricles in MO-Ecrg4 treated embryos. The H3P positive cells are on the ventricle surface and
there are more H3P cells and thicker GFAP staining in Ecrg4a MO. Scale bar is 100 μm F Quantification of cell growth in Zebrafish after control
or Ecrg4a morpholino injection. The amount of H3P-postive cell staining was determined as described in the text and compared between
treatment groups (n = 7, mean ± SEM). There were significantly more labeled cells in the Ecrg4a morpholino group. Scale bar is 100 μm.
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H3P immunoreactivity in embryos when Ecrg4 gene expres-
sion was knocked down (Figure 7F). Cross-sectional ana-
lyses (Figures 7E1 and 7E2) suggested that the distribution
of these proliferating cells is at the ventricular surface, and
co-localizes with increased glial fibrillary acidic protein
(GFAP) immunoreactivity. Taken together, these data sug-
gest that Ecrg4 gene knockdown dysinhibits cell prolifera-
tion of GFAP-positive cells. This finding is consistent with
(1) the inhibitory response observed with Ecrg4 over-
expression in rat brain (Figure 5D) and (2) the proliferative
response of endogenous NSPCs after injury (Figure 6D)
when augurin staining transiently disappears (Figures 4A
and 4B). We can therefore speculate that endogenous
augurin might regulate CNS cell proliferation, injury
response and, because its targets are progenitors, indirectly
control regeneration after CNS injury.
Discussion
In this study, we examined whether there are physiological
and pathophysiological consequences to the expression,
over-expression and knockdown of the Ecrg4 gene in the
CNS. The results across the four species evaluated (zebra-
fish, mouse, rat and human) are all consistent with the
hypothesis that augurin plays a physiological role in cell
growth, development and the injury response.
Immunohistochemical labeling of augurin and in situ
hybridization of Ecrg4 in mouse, rat and human brain tis-
sue sections (Figures 2, 3 and 4) showed that protein and
gene expression localize in large part, albeit not exclu-
sively, to CP and ependymal epithelial cells. Endogenous
Ecrg4 gene expression decreased in a cortical stab model
of CNS injury (Figure 4) and exogenous over-expression
via an injection of AdEcrg4 vector i.c.v. inhibited subepen-
dymal cell proliferation (Figure 5) that correlated with
decreased immunoreactivivity of nestin, a marker of
NSPCs (Figure 6). Finally, Ecrg4 gene knockdown using
RNA interference targeting Ecrg4a in zebrafish embryos
led to a hydrocephalus-like phenotype and increased
G F A P - p o s i t i v ec e l lp r o l i f e r a t i o n( F i g u r e7 ) .T h e s eo b s e r -
vations are all consistent with the hypothesis that augurin
can affect cell destiny in the CNS by controlling cell pro-
liferation of NSPCs: its presence is inhibitory and its
absence, dysinhibitory.
The transient loss of augurin staining after CNS injury
that we observed (Figure 4B) occurred at a time of sube-
pendymal progenitor cell proliferation [34]. Because the
injection of AdEcrg4 prevented this injury-induced loss of
augurin and decreased proliferation of NSPCs, we sug-
gest that there is a physiological link between the pro-
duction of augurin in the CPe and ependyma and
progenitor cells in the subependymal zone. The observa-
tion that Ecrg4 over-expression decreased nestin-positive
cell staining supports this hypothesis. Accordingly, all of
these observations are consistent with the hypothesis
that one biological activity of augurin is to control SVZ
cell response to injury.
The major peptide product of Ecrg4 gene expression in
the CP appears to be the 14 kDa peptide called augurin.
The immunoreactive band in mouse CP extracts resolved
at approximately this molecular weight and the form
produced by AdEcrg4 -transduced primary CPe cells
co-migrates with recombinant Ecrg4(31-148) produced in
E. coli (Figure 3C). The detection of 8 kDa and 28 kDa
immunoreactive peptides that correspond to argilin (Ecrg4
(71-148)) and an augurin dimer were also noted however.
We initially hypothesized that Ecrg4-derived peptides
might be involved in regulation of CSF formation, com-
position and hydrodynamics because CPe cells also
synthesize, secrete and respond to fluid homeostasis
peptide hormones including vasopressin, natriuretic fac-
tors, growth factors and endothelin-1 [42,43]. Bioinfor-
matic predictions also raised the possibility that the
Ecrg4 gene can encode several secreted neuropeptide-
like hormones in addition to augurin (see Figure 1) and
we hypothesized that each might have disparate and dis-
tinct biological activities. For example, we observed that
unlike CP, extracts of hypothalamus and neurohypophy-
sis contain an 8 kDa argilin rather than the 14 kDa
augurin [44]. Furthermore, argilin co-localized with fluid
homeostasis factors including arginine vasopressin, oxy-
tocin and atrial natriuretic peptide in the neurohypophy-
sis, supraoptic (SON) and paraventricular nuclei (PVN)
[45]. Tadross et al [46] demonstrated that this
C-terminal fragment of augurin [Ecrg4(71-148)] is a
secretagogue of corticotrophin-releasing hormone after
i.c.v. injection. The hydrocephalus-like phenotype
observed in developing zebrafish after gene knockdown
could therefore still support the hypothesis that one or
more of the peptide products of Ecrg4 are involved in
regulation of fluid balance. In light of the effects of
Ecrg4 expression on cell proliferation (BrdU) and differ-
entiation (nestin), it is more likely that this hydrocepha-
lus phenotype is caused by increased ventricular cell
proliferation resulting in obstruction of CSF flow and
drainage during development. Experiments designed to
further understand how Ecrg4 peptide products might
differentially affect fluid balance and/or cell growth and
differentiation are underway.
We presume augurin to be secreted by CPe and epen-
dyma in vivo because the ELISA data presented in Fig-
ure 3 show secretion by transduced primary CPe into
conditioned medium. Interestingly, other cultured cells
assessed in our laboratory do not secrete detectable
amounts of immunoreactive augurin into culture media.
Instead, neutravidin precipitation of biotin-labeled cell
surface proteins identifies a 14 kDa augurin that is
secreted, but retained, on the cell surface (unpublished
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ephrins, jagged and notch [47,48], has certain activities
that are related to its anchoring onto the plasma mem-
brane and cell-cell presentation. If so, even the 14 kDa
augurin may play multifunctional roles in the CPe and
ependyma depending on its bioavailability. To this end,
an evaluation of the patent literature reveals that the
Ecrg4 gene is one of very few genes identified in a differ-
ential analyses of feeder/non-feeder cell layers for their
capacity to support [49] the survival of progenitor cells.
Although several previous studies have now examined
Ecrg4 gene expression in cancer, bone development, and
more recently CNS aging, the studies described here
provide the first functional in vivo demonstration that
Ecrg4 expression is (1) necessary for normal CNS devel-
opment, (2) involved in the CNS injury response in
mammals and (3) regulates cell fate in the sub-ependy-
mal zone. In tumor cell models and in specimens
derived from human biopsies, Ecrg4 gene expression has
been related to the production of a putative secreted
tumor suppressor. Decreased Ecrg4 gene expression is
correlated with the transition from benign to malignant
tumor cell growth and the degree of Ecrg4 gene sup-
pression corresponds to aggressive growth [14]. The
data presented here suggest the Ecrg4 gene expression is
also involved in normal cell growth control and home-
ostasis. The constitutive production of augurin by CPe
and ependymal cells presumably maintains a baseline
growth inhibitory environment that maintains and
reduces resting cell proliferation rates. With this in
mind, any decreased Ecrg4 expression would create a
local “dysinhibitory niche” that would enable cell
responsiveness to other growth stimulatory factors.
Finally, it is important to note that there is a statisti-
cally significant correlation between the frequency of
cytosine-phosphate-guanine island methylation in the 5’
upstream non-coding region of the Ecrg4 gene and the
degree of malignancy in several types of cancers, includ-
ing choroid plexus papillomas and carcinoma [16,18,50].
As Ecrg4 gene expression is thought to be epigenetically
regulated in cancer by hyper-methylation [13-15,17,18], it
is particularly interesting to speculate that, in addition to
mechanisms like transcription factors that control the
response to injury, epigenetic dosing of the Ecrg4 gene
expression by methylation might serve to regulate
augurin production under physiological circumstances.
If so, the data presented here predict that these epige-
netic changes would dose subependymal progenitor cell
responsiveness after CNS injury. Accordingly, epigeneti-
cally-driven dosing of Ecrg4 gene expression would fore-
cast the ability of NSPCs to proliferate and predict
outcomes after CNS injury. To this end, it has not
escaped our attention that augurin agonists and antago-
nists of the putative peptide ligand, its putative receptor
and the control of its epigenetically regulated promoter
could generate next generation therapeutics that alter the
normal course of recovery after CNS neurodegeneration,
injury repair and regeneration.
Conclusions
We conclude that Ecrg4 gene expression is inversely
linked to the normal injury response in the CNS and
that an unusually elevated expression of the Ecrg4 gene
in the CP implies that its product, augurin, plays a role
in CP-CSF-CNS function. The facts that (1) Ecrg4
expression is decreased following CNS injury, (2) Ecrg4
over-expression is growth inhibitory in the subepen-
dyma and (3) Ecrg4 gene knockdown induces a hydroce-
phalus phenotype in development, also suggest a novel
role for augurin in the CP/ependymal biology. These
data are all consistent with a model whereby an injury-
induced decrease in augurin dysinhibits progenitor cells
at the ependymal-subependymal interface. If so, the
canonic control of its promoter by DNA methylation
implicates epigenetic mechanisms in neuroprogenitor
fate and function in the CNS.
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